Overview

A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

Inhaled amphotericin, a antifungal drug would decrease Aspergillus colonization and decrease the occurrence of exacerbations of Allergic Bronchopulmonary Aspergillosis (ABPA).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Postgraduate Institute of Medical Education and Research

Treatments:

Amphotericin B
Amphotericin B, deoxycholate drug combination
Budesonide
Formoterol Fumarate
Liposomal amphotericin B